Who are the top shareholders of the Nidan Laborator.?

The top shareholder of Nidan Laborator is Nitin Vitthalrao Thorve, holding 50.15% of shares. The highest public shareholder is Devendra Rajnikant Ladhani at 1.08%, while individual investors collectively own 39.78%.

The top shareholders of Nidan Laborator include the promoters, with Nitin Vitthalrao Thorve holding the largest share at 50.15%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Devendra Rajnikant Ladhani, who holds 1.08%. Additionally, individual investors collectively own 39.78% of the company.

how big is Nidan Laborator.?

As of Jun 06, Nidan Laboratories & Healthcare Ltd has a market capitalization of 29.00 Cr, categorizing it as a Micro Cap company, with recent net sales of 24.35 Cr and net profit of 2.89 Cr for the latest two quarters. Shareholder's funds are 66.21 Cr, and total assets are valued at 81.73 Cr as of Mar'24.

Market Cap: As of Jun 06, Nidan Laboratories & Healthcare Ltd has a market capitalization of 29.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest two quarters, which are Sep'21 and Jun'21, is 24.35 Cr. The sum of Net Profit for these quarters is 2.89 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending Mar'24. The Shareholder's Funds amount to 66.21 Cr, while the Total Assets are valued at 81.73 Cr.

What does Nidan Laborator. do?

Nidan Laboratories & Healthcare Ltd is a micro-cap company in the hospital industry, reporting net sales of 17 Cr and a net profit of 2 Cr for September 2021. It was incorporated in 2000 and rebranded in 2021, with a market cap of Rs 28 Cr.

Overview:<BR>Nidan Laboratories & Healthcare Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as Abhi Diagnostic Imagings Private Limited in 2000. It later changed its name to Nidan Laboratories And Healthcare Private Limited in March 2021. The most recent quarterly results reported net sales and net profit for September 2021.<BR><BR>Financial Snapshot:<BR>- Net Sales: 17 Cr (Quarterly Results - Sep 2021)<BR>- Net Profit: 2 Cr (Quarterly Results - Sep 2021)<BR>- Market-cap: Rs 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 15.00<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.14<BR>- Return on Equity: 2.99%<BR>- Price to Book: 0.44<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Nidan Laborator.?

As of March 2021, the management team of Nidan Laborator includes Edwin Francis Dabre (Executive Director), Tejal Anil Jayakar (Executive Director & CFO), Krupesh Deepak Thakur (Non-Executive Director), and several Independent Directors: Nilesh Ghanshyam Bide, Abhinay Shashikant Nerurkar, and Karim Hakam Khimani, along with Akshay Joshi as Company Secretary.

As of March 2021, the management team of Nidan Laborator includes the following members:<BR><BR>1. Edwin Francis Dabre - Executive Director<BR>2. Tejal Anil Jayakar - Executive Director & CFO<BR>3. Krupesh Deepak Thakur - Non Executive Director<BR>4. Nilesh Ghanshyam Bide - Independent Director<BR>5. Abhinay Shashikant Nerurkar - Independent Director<BR>6. Karim Hakam Khimani - Independent Director<BR>7. Akshay Joshi - Company Secretary<BR><BR>These individuals play key roles in the governance and management of the company.

When is the next results date for Nidan Laborator.?

No Upcoming Board Meetings

Has Nidan Laborator. declared dividend?

No Dividend History Available

Who are the peers of the Nidan Laborator.?

Nidan Laborator's peers include Max Healthcare, Apollo Hospitals, Fortis Health, and others, with varying management risks and growth rates. Nidan Laborator has below-average management risk and growth, with a 1-year return of 0.00%, similar to Docmode Health.

Peers: The peers of Nidan Laborator are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Soni Medicare, Broach, Docmode Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, and Krishna Institu., while Average management risk is found at Fortis Health., Aster DM Health., Broach, and Docmode Health. Below Average management risk is present at Soni Medicare and Nidan Laborator. For growth, Excellent growth is seen at Max Healthcare and Apollo Hospitals, Good growth at Fortis Health., Narayana Hrudaya, while Average growth is noted at Global Health and Broach, and Below Average growth is found at Aster DM Health., Krishna Institu., Soni Medicare, and Nidan Laborator. In terms of Capital Structure, Excellent capital structure is noted at Max Healthcare, Global Health, and Krishna Institu., Good capital structure at Fortis Health. and Broach, while Average capital structure is found at Apollo Hospitals, and Below Average at Aster DM Health., Soni Medicare, Docmode Health, and Nidan Laborator.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Soni Medicare at 124.83%, while the lowest is Docmode Health at 0.00%. Nidan Laborator's 1-year return is also 0.00%, indicating it is on par with Docmode Health. Additionally, Aster DM Health. and Broach have negative six-month returns.

What is the technical trend for Nidan Laborator.?

As of May 27, 2025, Nidan Laborator's technical trend is mildly bearish, influenced by mixed MACD signals and bearish Bollinger Bands.

As of 27 May 2025, the technical trend for Nidan Laborator has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish outlook. The daily moving averages are also mildly bearish. Bollinger Bands are bearish on both weekly and monthly time frames. The KST is mildly bullish weekly but bearish monthly, and there are no clear trends indicated by the Dow Theory or OBV. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and the bearish readings from Bollinger Bands.

Should I buy, sell or hold Nidan Laborator.?

How has been the historical performance of Nidan Laborator.?

Nidan Laborator's historical performance shows fluctuations, with net sales increasing slightly to 24.53 Cr in March 2025, while profit before tax rebounded to 2.76 Cr from a loss the previous year. Despite a profit recovery, cash flow from operating activities decreased to 2.00 Cr, indicating ongoing challenges.

Answer:<BR>The historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year.<BR><BR>Breakdown:<BR>Nidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negative the previous year. On the balance sheet, total assets slightly increased to 82.17 Cr in March 2025, while total liabilities rose marginally to 82.17 Cr. The company maintained a stable equity capital of 13.90 Cr over the years. Cash flow from operating activities decreased to 2.00 Cr in March 2025, down from 5.00 Cr in March 2024, indicating challenges in cash generation despite the overall profit recovery.

Is Nidan Laborator. overvalued or undervalued?

As of December 2, 2025, Nidan Laborator. is considered undervalued with a PE ratio of 15.76 and an attractive valuation grade, indicating potential for recovery despite a year-to-date return of -22.18%, especially when compared to higher PE ratios of peers like Max Healthcare and Apollo Hospitals.

As of 2 December 2025, Nidan Laborator. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 15.76, an EV to EBITDA of 8.27, and a Price to Book Value of 0.45. These ratios suggest that Nidan Laborator. is trading at a discount compared to its peers, particularly when compared to Max Healthcare, which has a PE ratio of 76.89, and Apollo Hospitals, with a PE of 62.27.<BR><BR>In the context of its industry, Nidan Laborator.'s valuation metrics stand out, especially given its low PEG ratio of 0.00, indicating no growth premium is being paid for future earnings. The company's return metrics, such as ROCE at 3.31% and ROE at 2.84%, further support the notion of undervaluation relative to its peers. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -22.18% compared to the Sensex's 10.10%, the attractive valuation suggests potential for recovery and growth.

Which are the latest news on Nidan Laborator.?

Why is Nidan Laborator. falling/rising?

As of 07-Dec, Nidan Laboratories & Healthcare Ltd's stock price has risen slightly to 20.20, outperforming its sector today. However, it has faced significant long-term challenges, with a -29.12% return over the past year and a -62.59% decline over the last three years, indicating persistent underperformance.

As of 07-Dec, Nidan Laboratories & Healthcare Ltd is experiencing a slight rise in its stock price, currently at 20.20, with a change of 0.15 (0.75%) upward. This increase can be attributed to its performance today, where it outperformed its sector by 1.24%. Additionally, the stock's current price is higher than its 50-day, 100-day, and 200-day moving averages, indicating a short-term positive trend.<BR><BR>However, despite this recent uptick, the stock has faced significant challenges over the longer term. Over the past year, it has generated a return of -29.12%, and its profits have decreased by 40%. The company has also shown weak long-term fundamental strength, as it has not declared results in the last six months and has a high Debt to EBITDA ratio of 3.36 times, indicating a low ability to service debt. Furthermore, the stock has consistently underperformed against the benchmark over the last three years, with a notable decline of -62.59% over the past three years compared to a 40.03% increase in the benchmark.<BR><BR>In summary, while there is a minor rise in the stock price today, the overall trend reflects significant long-term challenges and underperformance, which could overshadow the short-term gains.